Replicate Study design for Brazil [Regulatives / Guidelines]

posted by Weidson – Brazil, 2018-05-22 20:51 (1284 d 05:37 ago) – Posting: # 18799
Views: 1,888

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.


Best Regards
Weidson C. de Souza


Edit: Post moved. [Helmut]

Complete thread:

Activity
 Admin contact
21,778 posts in 4,555 threads, 1,547 registered users;
online 8 (0 registered, 8 guests [including 3 identified bots]).
Forum time: Saturday 01:28 CET (Europe/Vienna)

Every new technology to me is like a newborn baby –
and you think that it’s become president
or it’s cure cancer or win a nobel prize.
But in the end, you’re perfectly happy
when it just stays out of jail […].    Eric Betzig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5